Related references
Note: Only part of the references are listed.Membrane Mucin Muc4 promotes blood cell association with tumor cells and mediates efficient metastasis in a mouse model of breast cancer
A. R. Rowson-Hodel et al.
ONCOGENE (2018)
Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate
Govind Panchamoorthy et al.
JCI INSIGHT (2018)
MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma
Shailendra K. Gautam et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Vinod P. Balachandran et al.
NATURE (2017)
Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
Kristen M. Hege et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Mucin 2 silencing promotes colon cancer metastasis through interleukin-6 signaling
Hui-Ping Hsu et al.
SCIENTIFIC REPORTS (2017)
Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients
Carlo Fremd et al.
ONCOIMMUNOLOGY (2016)
A phase I study of PankoMab-GEX, a humanised glyco-optimised monoclonal antibody to a novel tumour-specific MUC1 glycopeptide epitope in patients with advanced carcinomas
W. Fiedler et al.
EUROPEAN JOURNAL OF CANCER (2016)
Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Avery D. Posey et al.
IMMUNITY (2016)
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
Elisabeth Quoix et al.
LANCET ONCOLOGY (2016)
MUC5AC interactions with integrin β4 enhances the migration of lung cancer cells through FAK signaling
I. Lakshmanan et al.
ONCOGENE (2016)
Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps
Juwon Park et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer
Lenneke A. M. Cornelissen et al.
BIOMOLECULES (2016)
The Role of Galectin-1 in Cancer Progression, and Synthetic Multivalent Systems for the Study of Galectin-1
Jonathan M. Cousin et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Selectins: initiators of leucocyte adhesion and signalling at the vascular wall
Rodger P. McEver
CARDIOVASCULAR RESEARCH (2015)
Antibody Induction Directed against the Tumor-Associated MUC4 Glycoprotein
Hui Cai et al.
CHEMBIOCHEM (2015)
90Y-clivatuzumab tetraxetan with or without low-dose gemcitabine: A phase Ib study in patients with metastatic pancreatic cancer after two or more prior therapies
Vincent J. Picozzi et al.
EUROPEAN JOURNAL OF CANCER (2015)
A novel monoclonal antibody to a defined peptide epitope in MUC16
Lara Marcos-Silva et al.
GLYCOBIOLOGY (2015)
Suppression of Toll-like receptor-mediated innate immune responses at the ocular surface by the membrane-associated mucins MUC1 and MUC16
B. B. Menon et al.
MUCOSAL IMMUNOLOGY (2015)
Salivary mucins induce a Toll-like receptor 4-mediated pro-inflammatory response in human submandibular salivary cells: are mucins involved in Sjogren's syndrome?
Maria-Jose Barrera et al.
RHEUMATOLOGY (2015)
Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells
Imayavaramban Lakshmanan et al.
ONCOTARGET (2015)
Glycosylation in cancer: mechanisms and clinical implications
Salome S. Pinho et al.
NATURE REVIEWS CANCER (2015)
Radioimmunotherapy of human tumours
Steven M. Larson et al.
NATURE REVIEWS CANCER (2015)
MUC1 Protein Induces Urokinase-type Plasminogen Activator (uPA) by Forming a Complex with NF-κB p65 Transcription Factor and Binding to the uPA Promoter, Leading to Enhanced Invasiveness of Cancer Cells
Yugo Mori et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress
Mildred Felder et al.
MOLECULAR CANCER (2014)
Pancreatic cancer counterattack: MUC4 mediates Fas-independent apoptosis of antigen-specific cytotoxic T lymphocyte
Yi Zhu et al.
ONCOLOGY REPORTS (2014)
The Role of PAM4 in the Management of Pancreatic Cancer: Diagnosis, Radioimmunodetection, and Radioimmunotherapy
Suxia Han et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Altered tumor-cell glycosylation promotes metastasis
Irina Hauselmann et al.
FRONTIERS IN ONCOLOGY (2014)
L-BLP25 as a peptide vaccine therapy in non-small cell lung cancer: a review
Wenjie Xia et al.
JOURNAL OF THORACIC DISEASE (2014)
Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models
Sandip Pravin Patel et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
MUC5AC protects pancreatic cancer cells from TRAIL-induced death pathways
Hirotaka Hoshi et al.
INTERNATIONAL JOURNAL OF ONCOLOGY (2013)
Mapping PAM4 (clivatuzumab), a monoclonal antibody in clinical trials for early detection and therapy of pancreatic ductal adenocarcinoma, to MUC5AC mucin
David V. Gold et al.
MOLECULAR CANCER (2013)
Mucins in pancreatic cancer and its microenvironment
Sukhwinder Kaur et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2013)
Tumour Immunomodulation: Mucins in Resistance to Initiation and Maturation of Immune Response Against Tumours
A. AnandKumar et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2013)
Mucus Enhances Gut Homeostasis and Oral Tolerance by Delivering Immunoregulatory Signals
Meimei Shan et al.
SCIENCE (2013)
Mesothelin Binding to CA125/MUC16 Promotes Pancreatic Cancer Cell Motility and Invasion via MMP-7 Activation
Shih-Hsun Chen et al.
SCIENTIFIC REPORTS (2013)
Immunotherapy with IL-10-and IFN-γ-producing CD4 effector cells modulate Natural and Inducible CD4 TReg cell subpopulation levels: observations in four cases of patients with ovarian cancer
Mark J. Dobrzanski et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Mucins and Toll-like receptors: Kith and kin in infection and cancer
Shikha Tarang et al.
CANCER LETTERS (2012)
Mucin 16 is a functional selectin ligand on pancreatic cancer cells
Shih-Hsun Chen et al.
FASEB JOURNAL (2012)
Cancer Associated Aberrant Protein O-Glycosylation Can Modify Antigen Processing and Immune Response
Caroline B. Madsen et al.
PLOS ONE (2012)
Immune recognition of tumor-associated mucin MUC1 is achieved by a fully synthetic aberrantly glycosylated MUC1 tripartite vaccine
Vani Lakshminarayanan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings
Stephane Oudard et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Novel Interaction of MUC4 and Galectin: Potential Pathobiological Implications for Metastasis in Lethal Pancreatic Cancer
Shantibhusan Senapati et al.
CLINICAL CANCER RESEARCH (2011)
Randomized Phase II Trial of Letrozole plus Anti-MUC1 Antibody AS1402 in Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer
Nuhad K. Ibrahim et al.
CLINICAL CANCER RESEARCH (2011)
Treatment of Advanced Pancreatic Carcinoma with 90Y-Clivatuzumab Tetraxetan: A Phase I Single-Dose Escalation Trial
Seza A. Gulec et al.
CLINICAL CANCER RESEARCH (2011)
MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer
Sherven Sharma et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
MUC16 (CA125) regulates epithelial ovarian cancer cell growth, tumorigenesis and metastasis
Catherine Theriault et al.
GYNECOLOGIC ONCOLOGY (2011)
Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial
Elisabeth Quoix et al.
LANCET ONCOLOGY (2011)
Preparation and biological evaluation of 177Lu conjugated PR81 for radioimmunotherapy of breast cancer
Mojtaba Salouti et al.
NUCLEAR MEDICINE AND BIOLOGY (2011)
Monoclonal Antibodies Recognizing the Non-Tandem Repeat Regions of the Human Mucin MUC4 in Pancreatic Cancer
Maneesh Jain et al.
PLOS ONE (2011)
Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Hong Song et al.
CURRENT DRUG DELIVERY (2011)
Autoantibodies to aberrantly glycosylated MUC1 in early stage breast cancer are associated with a better prognosis
Ola Blixt et al.
BREAST CANCER RESEARCH (2011)
Immunomodulation of monocyte-derived dendrite cells through ligation of tumor-produced mucins to Siglec-9
Mariko Ohta et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Deletion of the Mucin-Like Molecule Muc1 Enhances Dendritic Cell Activation in Response to Toll-Like Receptor Ligands
Marc A. Williams et al.
JOURNAL OF INNATE IMMUNITY (2010)
MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells
Jennifer A. A. Gubbels et al.
MOLECULAR CANCER (2010)
Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas
Xiao-Na Fan et al.
PATHOLOGY RESEARCH AND PRACTICE (2010)
Identification of an HLA-A*0201-restrictive CTL epitope from MUC4 for applicable vaccine therapy
Junli Wu et al.
IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY (2009)
MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure
R. Dreicer et al.
INVESTIGATIONAL NEW DRUGS (2009)
Oregovomab Maintenance Monoimmunotherapy Does Not Improve Outcomes in Advanced Ovarian Cancer
Jonathan Berek et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification of O-glycosylated decapeptides within the MUC1 repeat domain as potential MHC class I (A2) binding epitopes
Tanja Ninkovic et al.
MOLECULAR IMMUNOLOGY (2009)
Mucins in ovarian cancer diagnosis and therapy
Subhash C. Chauhan et al.
JOURNAL OF OVARIAN RESEARCH (2009)
Mucins in cancer: function, prognosis and therapy
Donald W. Kufe
NATURE REVIEWS CANCER (2009)
Toll-like receptors and cancer
Seth Rakoff-Nahoum et al.
NATURE REVIEWS CANCER (2009)
Bismuth-213 radioimmunotherapy with C595 anti-MUC1 monoclonal antibody in an ovarian cancer ascites model
Emma Y. Song et al.
CANCER BIOLOGY & THERAPY (2008)
MUC4 mucin interacts with and stabilizes the HER2 oncoprotein in human pancreatic cancer cells
Pallavi Chaturvedi et al.
CANCER RESEARCH (2008)
A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV non-small cell lung cancer
Rodryg Ramlau et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Clinical potential of mucins in diagnosis, prognosis, and therapy of ovarian cancer
Ajay P. Singh et al.
LANCET ONCOLOGY (2008)
Mucin Dynamics in Intestinal Bacterial Infection
Sara K. Linden et al.
PLOS ONE (2008)
Peritoneal natural killer cells from epithelial ovarian cancer patients show an altered phenotype and bind to the tumour marker MUC16 (CA125)
Jennifer A. Belisle et al.
IMMUNOLOGY (2007)
Robust immune responses elicited by a fully synthetic three-component vaccine
Sampat Ingale et al.
NATURE CHEMICAL BIOLOGY (2007)
The MUC1 and galectin-3 oncoproteins function in a MicroRNA-dependent regulatory loop
Selvi Ramasamy et al.
MOLECULAR CELL (2007)
L-BLP25: A peptide vaccine strategy in non-small cell lung cancer
Randeep Sangha et al.
CLINICAL CANCER RESEARCH (2007)
MUC1 cell surface mucin is a critical element of the mucosal barrier to infection
Julie L. McAuley et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Engineering antibodies for clinical applications
Maneesh Jain et al.
TRENDS IN BIOTECHNOLOGY (2007)
PankoMab:: a potent new generation anti-tumour MUC1 antibody
Antje Danielczyk et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Synthesis and structural model of an α(2,6)-sialyl-T glycosylated MUC1 eicosapeptide under physiological conditions
Sebastian Dziadek et al.
CHEMISTRY-A EUROPEAN JOURNAL (2006)
Pharmacokinetics, biodistribution, and radioimmunotherapy with monoclonal antibody 776.1 in a murine model of human ovarian cancer
MA Berger et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2005)
Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125
MS Patankar et al.
GYNECOLOGIC ONCOLOGY (2005)
Malignancy-induced autoimmunity to MUC1:: initial antibody characterization
CRL Graves et al.
JOURNAL OF PEPTIDE RESEARCH (2005)
A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer
TG Ehlen et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2005)
In vivo and in vitro inhibition of pancreatic cancer growth by targeted alpha therapy using 213Bi-CHX.A-C595
CF Qu et al.
CANCER BIOLOGY & THERAPY (2005)
Recombinant tumor-associated MUC1 glycoprotein impairs the differentiation and function of dendritic cells
A Rughetti et al.
JOURNAL OF IMMUNOLOGY (2005)
Engineering and characterization of a divalent single-chain Fv angiotensin II fusion construct of the monoclonal antibody CC49
UA Wittel et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and bovine serum albumin
S Dziadek et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2005)
Penetratin improves tumor retention of single-chain antibodies: A novel step toward optimization of radioimmunotherapy of solid tumors
M Jain et al.
CANCER RESEARCH (2005)
Combined 90yttrium-DOTA-labeled PAM4 antibody radioimmunotherapy and gemcitabine radiosensitization for the treatment of a human pancreatic cancer xenograft
DV Gold et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Generation and characterization of anti-MUC4 monoclonal antibodies reactive with normal and cancer cells in humans
N Moniaux et al.
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY (2004)
Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)
U Karsten et al.
GLYCOBIOLOGY (2004)
Mucins in cancer: Protection and control of the cell surface
MA Hollingsworth et al.
NATURE REVIEWS CANCER (2004)
Tumor-derived MUC1 mucins interact with differentiating monocytes and induce IL-10high IL-12low regulatory dendritic cell
P Monti et al.
JOURNAL OF IMMUNOLOGY (2004)
Multiple roles of mucins in pancreatic cancer, a lethal and challenging malignancy
N Moniaux et al.
BRITISH JOURNAL OF CANCER (2004)
A glycopeptide in complex with MHC class I uses the GaINAc residue as an anchor
V Apostolopoulos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Epitope mapping of antigenic MUC1 peptides to breast cancer antibody fragment B27.29: A heteronuclear NMR study
JS Grinstead et al.
BIOCHEMISTRY (2003)
O-linked glycans control glycoprotein processing by antigen-presenting cells: a biochemical approach to the molecular aspects of MUC1 processing by dendritic cells
FG Hanisch et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
Mucin gene (MUC1) transfected dendritic cells as vaccine:: results of a phase I/II clinical trial
G Pecher et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2002)
Pharmacokinetics and biodistribution of genetically engineered antibodies
SK Batra et al.
CURRENT OPINION IN BIOTECHNOLOGY (2002)
Principles of mucin architecture: Structural studies on synthetic glycopeptides bearing clustered mono-, di-, tri-, and hexasaccharide glycodomains
DM Coltart et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2002)
Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewisa and sialyl-Lewisx antigens in colorectal adenocarcinoma
SE Baldus et al.
HISTOPATHOLOGY (2002)
Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma
S Supiot et al.
CANCER (2002)
Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1
C Musselli et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Combined gemcitabine and radioimmunotherapy for the treatment of pancreatic cancer
TM Cardillo et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Mucin antibodies - New tools in diagnosis and therapy of cancer
UA Wittel et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2001)
Localization of pancreatic cancer with radiolabeled monoclonal antibody PAM4
DV Gold et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2001)
Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13 - Evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo
AA Noujaim et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2001)
Imaging for staging bladder cancer: a clinical study of (111)indium-labelled anti-MUC1 mucin intravenous monoclonal antibody C595
ODM Hughes et al.
BJU INTERNATIONAL (2001)
Humoral immune response induced by the protein core of MUC1 mucin in pregnant and healthy women
MV Croce et al.
BREAST CANCER RESEARCH AND TREATMENT (2001)
The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells
EM Hiltbold et al.
JOURNAL OF IMMUNOLOGY (2000)
Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin
S von Mensdorff-Pouilly et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Targeting superficial bladder cancer by the intravesical administration of copper-67-labeled anti-MUC1 mucin monoclonal antibody C595
ODM Hughes et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
